Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review.

Jingjing LvHui WuJunjie XuJiaye Liu

Published in: Infectious diseases of poverty (2022)

Heterologous ChAd/BNT schedule induced at least comparable immunogenicity compared with homologous BNT/BNT and better immunogenicity compared with homologous ChAd/ChAd vaccination. The synthetical evidence supported the general application of heterologous prime-boost vaccination using ChAd and BNT COVID-19 vaccines.

Keyphrases

coronavirus disease
dna repair
sars cov
dna damage
saccharomyces cerevisiae
high glucose
respiratory syndrome coronavirus
oxidative stress
drug induced
binding protein